Thyroid Cancer Screening (PDQ®)
Based on solid evidence, screening for thyroid cancer does not result in a decrease in thyroid cancer mortality.
This PDQ cancer information summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about thyroid cancer screening. It is intended as a resource to inform and assist clinicians in the care of their patients and does not provide formal guidelines or recommendations for making health care decisions.
Though a large number of screening examinations are performed, no evidence shows that screening reduces mortality, indicating that screening may not improve patient outcomes and could expose patients to unnecessary harms such as overdiagnosis, overtreatment, and anxiety.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management